This year, during the Multidisciplinary Head and Neck Cancer Symposium, being held at the JW Marriott Camelback Inn Resort & Spa in Scottsdale, Arizona, February 20 – 22, 2014, experts and key opinion leaders explore the multidisciplinary treatment approach of head and neck cancer, cover novel molecular biologic therapies showing promise in improving outcomes, teach cutting-edge science, share new inshight in supportive care and directed therapy, and provide updates on clinical trials, toxicity mitigation and new surgical and radiotherapeutic techniques.
The symposium, sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS), looks at the heterogeneous group of tumors in head and neck cancers, and the various complexities and factors in providing treatment. The multidisciplinary approach includes surgery, radiation therapy and chemotherapy in addition to novel molecular biologic therapies that show promise in improving outcomes.
This year, a total of 189 abstracts were presented including 177 scientific posters.
Treatment SOS: Help for Laryngectomees
During the Multidisciplinary Head and Neck Cancer Symposium, Joni Aldrich, host of Cancer Radio – a cancer talk call-in radio show – spoke with Itzhak Brook, MD, MSc, Adjunct Professor of Pediatrics and Medicine at Georgetown University School of Medicine, Washington DC.
In an incredible interview, Professor Brook shared his experience as a survivor of throat cancer and as a laryngectomee. Professor Brook also talked about prevention, symptoms, finding the right treatment and the challenges that laryngectomee’s face after treatment. To listen to the program, click on the link below.
Join the conversation
In this Onco’Zine Dossier we share with you the highlights of the 2014 Multidisciplinary Head and Neck Cancer Symposium. Read the articles, listen to the unique interview with Professor Brook and, following your discovery, go to Facebook, Twitter and LinkedIn and share your ideas and comments.
- Unilateral Radiation may Results in more Favorable Outcomes in Patients with Advanced Stage Tonsil Cancer [Article]
- Limiting Radiation Dose to the Glottic Larynx Beneficial for Patients with Oropharyngeal Cancer [Article]
- Preliminary Evidence Suggest that Limiting Radiation to Major Salivary Glands in Head and Neck Cancer Patients is Feasible and Safe [Article]
- Mutant-Allele Tumor Heterogeneity and HPV Status in Head and Neck Squamous Cell Carcinoma Effective Marker of Improved Patient Outcome [Article]
- Reduction of Radiation Dose to Bilateral IB Lymph Nodes Improves Salivary Function in Patients with Oropharyngeal Cancer [Article]
- Study Show HPV-positive Oropharyngeal Cancer Patients Nearly Twice as Likely to Survive as HPV-negative Patients [Article]
- Study Shows Head and Neck Cancer Patients Benefit from Daily Humidification of the Mouth and Throat Region During Radiation Therapy [Article]
Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.